Physician profile
Hannah E Miller
NPI 1710465604
$11,233.44
in general payments reported to CMS, 2019-2025
24 companies · $2,504 in 2025
The $2,504 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,771 · 2022: $1,886 · 2023: $2,928 · 2024: $2,144 · 2025: $2,504.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,233 · Education: $343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,233.15 |
| Education | $343.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,879.14 | 2021-2025 | |
| Lilly USA, LLC | $1,200.94 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $1,174.74 | 2021-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $1,130.22 | 2021-2025 | Tremfya, Simponi Aria, Stelara |
| Genzyme Corporation | $781.54 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $703.91 | 2021-2025 | Winlevi, Absorica Ld |
| Ucb, INC. | $667.98 | 2024-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $659.97 | 2022-2025 | Sotyktu |
| Amgen INC. | $555.32 | 2021-2025 | Otezla, Otezla, Enbrel |
| Novartis Pharmaceuticals Corporation | $536.08 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $349.13 | 2021-2022 | |
| Arcutis Biotherapeutics, INC. | $343.64 | 2023-2025 | Zoryve |
| Incyte Corporation | $314.89 | 2022-2025 | Opzelura |
| Galderma Laboratories, L.P. | $215.30 | 2021-2025 | Nemluvio, Aklief |
| Leo Pharma INC. | $181.54 | 2021-2025 | Adbry |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $168.53 | 2021-2025 | |
| Vyne Pharmaceuticals INC. | $112.98 | 2021 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2022 | |
| Dermavant Sciences, INC. | $54.84 | 2023 | Vtama |
| Organon LLC | $36.97 | 2025 | |
| Dermira, INC. | $25.24 | 2021 | |
| Ani Pharmaceuticals, INC. | $23.60 | 2025 | Purified Cortrophin Gel |
| Biofrontera INC. | $23.05 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
| Glaxosmithkline, LLC. | $13.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.